Exagen Inc. Reports Third Quarter 2021 Results
SAN DIEGO, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2021.
Third Quarter Highlights:
- Generated total revenue of $12.3 million for the third quarter of 2021, a 14% increase over the third quarter of 2020.
- Our flagship AVISE® CTD test, including AVISE® Lupus, generated revenue of $9.9 million for the third quarter of 2021. This represents a 34% increase over the third quarter of 2020.
- Delivered 31,742 AVISE® CTD tests, including AVISE® Lupus, in the third quarter of 2021, a 21% increase over the third quarter of 2020.
- Record number of ordering healthcare providers totaling 1,969 in the third quarter of 2021.
- Record of 714 adopters, and sequential quarterly retention rate of approximately 99% among adopting healthcare providers from the prior quarter.
“Exagen continues to achieve record results with our number of ordering healthcare providers and adopters. Our world class research and development team continues to drive our science, as demonstrated by the eight key abstracts that were accepted by the American College of Rheumatology conference. Additionally, we are pleased to expand payor access by signing an agreement with Inland Empire Health Plan, which increased our in-network lives to approximately 68.9 million,” said Ron Rocca, President and Chief Executive Officer of Exagen. “We are also happy to announce that we have entered into a pilot agreement to supply AVISE® MTX to a partnership between a retail pharmacy chain and a major payor to advance personalized medicine for patients with rheumatoid arthritis. These accomplishments further our mission of reducing time-to-treatment and improving patient outcomes.”
Third Quarter 2021 Financial Results
Revenue for the three months ended September 30, 2021 was $12.3 million, compared with $10.8 million in the third quarter of 2020. Testing revenue was $11.9 million for the third quarter of 2021, compared to $9.5 million in the third quarter of 2020, due to increased testing volumes. Our SIMPONI® co-promotion efforts contributed $0.4 million in the third quarter of 2021, compared to $1.3 million in the third quarter of 2020. Gross margin was 55% in the third quarter of 2021 compared to 60% in the third quarter of 2020, driven by the decrease in co-promotion revenue.
Operating expenses were $18.8 million in the third quarter of 2021, compared with $14.6 million in the third quarter of 2020, due to increases in employee related expenses from headcount growth, including stock-based compensation, cost of revenue due to the increase in testing volumes, and research and development expenses.
For the third quarter of 2021, net loss was $7.2 million, compared to a net loss of $4.3 million for the third quarter of 2020.
Cash and cash equivalents were approximately $106.8 million as of September 30, 2021.
For the full year 2021, Exagen reaffirms its prior guidance and expects revenue to be in the range of $47 million to $49 million.
A conference call to review third quarter 2021 financial results and to provide a business update is scheduled for today November 10, 2021 at 4:30 PM ET (1:30 PM PT). Interested parties may access the conference call by dialing (844) 826-3033 (U.S.) or (412) 317-5185 (international). Additionally, a link to a live webcast of the call will be available in the Investor Relations section of Exagen’s website at http://investors.exagen.com.
Participants are asked to join a few minutes prior to the call to register for the event. A replay of the conference call will be available until Wednesday, November 17, 2021 at 11:59 PM ET (8:59 PM PT). Interested parties may access the replay by dialing (844) 512-2921 (U.S.) or (412) 317-6671 (international) using passcode 10161457. A link to the replay of the webcast will also be available in the investor relations section of Exagen’s website.
Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. Exagen has developed and is commercializing a portfolio of innovative testing products under its AVISE® brand, several of which are based on our proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. Exagen’s goal is to enable providers to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including rheumatoid arthritis and lupus. For more information, please visit www.Exagen.com.
Forward Looking Statements
Exagen cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on Exagen’s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding: Exagen’s goals and strategies; the potential utility and effectiveness of Exagen’s services and testing solutions; evaluations and judgements regarding published abstracts; the ability of the company to secure wider reimbursement for its tests; the expected impact and results of further investments in our business and collaborations, including the pilot agreement; Exagen’s future potential growth in 2021; and the 2021 guidance. The inclusion of forward-looking statements should not be regarded as a representation by Exagen that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Exagen’s business, including, without limitation: the COVID-19 pandemic may continue to adversely affect our business, financial condition and results of operations, including as a result of shutdowns of our facilities and operations as well as those of our suppliers and courier services, impeding patient movement and interruptions to healthcare services causing a decrease in test volumes, disruptions to the supply chain of material needed for our tests, our sales and commercialization activities and our ability to receive specimens and perform or deliver the results from our tests, delays in reimbursement and coverage decisions from Medicare and third-party payors and in interactions with regulatory authorities, and delays in ongoing and planned clinical trials involving our tests; the company’s commercial success depends upon attaining and maintaining significant market acceptance of its testing products and promoted therapeutics among rheumatologists, patients, third-party payors and others in the medical community; the company’s ability to successfully execute on its business strategies, including its strategy of integrating the promotion of its existing and future proprietary testing products with the promotion of therapeutics; third-party payors not providing coverage and adequate reimbursement for the company’s testing products or promoted therapeutics; the company’s ability to obtain and maintain intellectual property protection for its testing products; regulatory developments affecting the company’s business; and other risks described in the company’s prior press releases and the company’s filings with the Securities and Exchange Commission (“SEC”), including under the heading “Risk Factors” in Exagen’s Annual Report on Form 10-K for the year ended December 31, 2020 and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Exagen undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Kamal Adawi, Chief Financial Officer
Unaudited Condensed Statements of Operations
(in thousands, except share and per share data)
|Three Months Ended September 30,||Nine Months Ended September 30,|
|Costs of revenue||5,487||4,341||15,649||12,224|
|Selling, general and administrative expenses||11,528||9,202||32,739||27,104|
|Research and development expenses||1,740||1,018||5,035||2,403|
|Total operating expenses||18,755||14,561||53,423||41,731|
|Loss from operations||(6,504||)||(3,786||)||(17,813||)||(12,424||)|
|Other income, net||3||125||1||985|
|Loss before income taxes||(7,179||)||(4,308||)||(19,798||)||(13,352||)|
|Income tax benefit||—||—||—||118|
|Net loss per share, basic and diluted||$||(0.42||)||$||(0.34||)||$||(1.27||)||$||(1.05||)|
|Weighted-average number of shares used to compute net loss per share, basic and diluted||16,945,591||12,644,348||15,636,150||12,626,259|
Condensed Balance Sheets
(in thousands, except share and per share data)
|September 30, 2021||December 31, 2020|
|Cash and cash equivalents||$||106,766||$||57,448|
|Accounts receivable, net||9,210||8,910|
|Prepaid expenses and other current assets||2,405||4,159|
|Total current assets||118,381||70,517|
|Property and equipment, net||3,446||2,102|
|Liabilities and Stockholders' Equity|
|Accrued and other current liabilities||6,584||5,757|
|Total current liabilities||8,096||8,771|
|Borrowings-non-current portion, net of discounts and debt issuance costs||27,288||26,659|
|Deferred tax liabilities||158||158|
|Other non-current liabilities||1,427||948|
|Commitments and contingencies|
|Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued or outstanding at September 30, 2021 and December 31, 2020||—||—|
|Common stock, $0.001 par value; 200,000,000 shares authorized at September 30, 2021 and December 31, 2020; 16,164,232 and 12,652,308 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively||16||13|
|Additional paid-in capital||291,874||223,115|
|Total stockholders' equity||90,803||41,839|
|Total liabilities and stockholders' equity||$||127,772||$||78,375|